AR040683A1 - Composicion de tabletas de liberacion sostenida que comprende un agonista de los receptores de la dopamina - Google Patents

Composicion de tabletas de liberacion sostenida que comprende un agonista de los receptores de la dopamina

Info

Publication number
AR040683A1
AR040683A1 AR20030102668A ARP030102668A AR040683A1 AR 040683 A1 AR040683 A1 AR 040683A1 AR 20030102668 A AR20030102668 A AR 20030102668A AR P030102668 A ARP030102668 A AR P030102668A AR 040683 A1 AR040683 A1 AR 040683A1
Authority
AR
Argentina
Prior art keywords
sustained release
chbr
chcl
chf
chi
Prior art date
Application number
AR20030102668A
Other languages
English (en)
Inventor
Loksidh Ganorkar
Joseph Reo
Alice Maritno
Gregory Amidon
Connie Skoug
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of AR040683A1 publication Critical patent/AR040683A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composición farmacéutica de liberación sostenida en forma de una tableta administrable por vía oral comprende como agente farmacéutico activo un compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo, donde R1,R2 y R3 son iguales o distintos y son H, alquilo C1-6 (opcionalmente sustituido con fenilo), alquenilo o alquinilo C3-5 ó cicloalquilo C3-10, o donde R3 es el mismo que anteriormente y R1 y R2 están ciclados con el átomo de N ligado para formar grupos pirrolodinilo, piperidinilo, morfolinilo, 4-metilpiperazinilo o imidazolilo; X es H, F, Cl, Br, I, OH, alquilo o alcoxi C1-6, CN, carboxamida, carboxilo o (alquilo C1-6)carbonilo; A es CH, CH2, CHF, CHCl, CHBr, CHI, CHCH3, C=O, C=S, CSCH3, C=NH, CNH2, CNHCH3, CNHCOOCH3, CNHCN, SO2 o N; B es CH, CH2, CHF, CHCl, CHBr, CHI, C=O, N, NH o NCH3, y n es 0 ó 1; y D es CH, CH2, CHF, CHCl, CHBr, CHI, C=O, O, N, NH o NCH3. El agente está dispersado en una matriz que comprende un polímero hidrófilo y un almidón que tiene una resistencia a la tensión de al menos aproximadamente 0,15 KN cm-2 en una fracción sólida representativa de la tableta. La composición presenta propiedades de liberación sostenida eficaces para el tratamiento de la enfermedad de Parkinson. La tableta se recubre opcionalmente. Las tabletas tienen una mejor resistencia a la abrasión o al desgaste durante su fabricación, empaquetamiento y manejo.
AR20030102668A 2002-07-25 2003-07-24 Composicion de tabletas de liberacion sostenida que comprende un agonista de los receptores de la dopamina AR040683A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39842702P 2002-07-25 2002-07-25
US39844702P 2002-07-25 2002-07-25
US47932703P 2003-06-18 2003-06-18

Publications (1)

Publication Number Publication Date
AR040683A1 true AR040683A1 (es) 2005-04-13

Family

ID=31192086

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20030102668A AR040683A1 (es) 2002-07-25 2003-07-24 Composicion de tabletas de liberacion sostenida que comprende un agonista de los receptores de la dopamina

Country Status (13)

Country Link
US (1) US20050079217A1 (es)
EP (1) EP1539165A1 (es)
JP (1) JP2005537286A (es)
KR (1) KR20050043894A (es)
CN (1) CN1671388A (es)
AR (1) AR040683A1 (es)
AU (1) AU2003261265A1 (es)
BR (1) BR0312891A (es)
CA (1) CA2493179A1 (es)
MX (1) MXPA05001055A (es)
TW (1) TW200412961A (es)
WO (1) WO2004011002A1 (es)
ZA (1) ZA200500438B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101155B2 (en) 2003-07-11 2015-08-11 Asahi Kasei Chemicals Corporation Functional starch powder

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273975A (en) * 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
KR0167346B1 (ko) * 1989-06-09 1999-01-15 로버트 에이. 아미테이지 중추신경계 활성을 갖는 헤테로사이클릭 아민
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
CA2211778A1 (en) * 1997-08-14 1999-02-14 Francois Carriere Preparation of pregelatinized high amylose starch and debranched starch useful as an excipient for controlled release of active agents
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
GB9802201D0 (en) * 1998-02-03 1998-04-01 Cerestar Holding Bv Free-flowable directly compressible starch as binder,disintegrant and filler for compresion tablets and hard gelatine capsules
JP2002506031A (ja) * 1998-03-11 2002-02-26 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 組成物
EP1169024B1 (en) * 1999-03-31 2005-12-21 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas

Also Published As

Publication number Publication date
TW200412961A (en) 2004-08-01
MXPA05001055A (es) 2005-04-08
US20050079217A1 (en) 2005-04-14
CA2493179A1 (en) 2004-02-05
AU2003261265A1 (en) 2004-02-16
CN1671388A (zh) 2005-09-21
KR20050043894A (ko) 2005-05-11
ZA200500438B (en) 2006-08-30
JP2005537286A (ja) 2005-12-08
BR0312891A (pt) 2005-06-14
WO2004011002A1 (en) 2004-02-05
EP1539165A1 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
ECSP088863A (es) Compuestos que son agonistas de receptores muscarínicos y que pueden ser eficaces en el tratamiento del dolor, la enfermedad de alzheimer y/o la esquizofrenia
PE20081374A1 (es) Combinacion que comprende un agente antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina
JP2007145875A5 (es)
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
UA93543C2 (ru) Применение дозированной лекарственной формы, которая содержит оксикодон и налоксон
GEP20094723B (en) Tetraazabenzo [e] azulene derivatives and analogs thereof
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
UY27127A1 (es) Derivados de la urea como antagonistas de integrin alfa-4
TR201910180T4 (tr) Sinakalset HCI'nin hızlı çözünme formülasyonu.
HRP20171384T4 (hr) Farmaceutski pripravak
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
ECSP066314A (es) Derivados piridilo y su uso como agentes terapéuticos
MY130803A (en) New quinuclidine amide derivatives
WO2003010159A8 (en) Piperidine derivatives as nmda receptor antagonists
MY141939A (en) Pyridazine derivatives and their use as therapeutic agents
BRPI0410649A (pt) benzo(b) tiofeno 3-arilóxi e 3-heteroarilóxi substituìdos como agentes terapêuticos com atividade pi3k
JP2009541443A5 (es)
YU36403A (sh) Soli izotiazol-4-karboksamida kao anti-hiperproliferacioni agensi
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
EA200801245A1 (ru) [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины и формы и способы, связанные с ними
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
PE20001084A1 (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas
AR038618A1 (es) Forma poliformica cristalina de clorhidratos de irinotecan

Legal Events

Date Code Title Description
FA Abandonment or withdrawal